For Key Opinion Leaders (KOLs)

Hematologists, Oncologists, Autoimmunity Experts, Academic Researchers, Biologists, etc.

AVM0703 selectively ablates T and B lymphocytes and monocytes, and lymphodepletes neutrophils at the target clinical dose.  Basophils (reduced only at the 6 hour time point) and eosinophils (reduced only at the 24 and 48 hour time points), platelets, RBCs are spared, and HSC and MSC are spared or increased.

For Patients and their Loved Ones

Relapsed/Refractory Lymphocytic Blood Cancer and Non-responding Autoimmune Patients and their Loved Ones

We at AVM believe that there should be a treatment option that allows you to have a good quality of life with your loved ones without exhausting your financials.

For Business Leaders & Potential Investors

The ability to be able to replace toxic chemotherapy represents investing and partnering opportunity that is not only significant in monetary value but also impactful in social value. 

In the U.S. alone, total patients who can be treated with AVM0703 represent a $30B dollar annual revenue opportunity. 

AVM0703 Has the Most Favorable Lymphodepletion Profile

Cy/Flu

  • No Bone Marrow Redistribution
  • Deplete Peripheral Blood Lymph
  • Decrease Adoptive Cell Transfer (ACT) Binding in Spleen
  • Decrease Thymocytes
  • Increase in IL-2, IL-7, IL-12 and IL-15
  • Decrease Endogenous HSCs and MSCs
  • Increase in IL-6 and GM-CSF
  • Deplete Neutrophils, Platelets and RBCs
  • CRS, neuroedema, angiodema, fatal infusion reactions

AVM0703

  • No Bone Marrow Redistribution
  • Deplete Peripheral Blood Lymph
  • Decrease Adoptive Cell Transfer (ACT) Binding in Spleen
  • Decrease Thymocytes
  • Increase in IL-2, IL-7, IL-12 and IL-15
  • Increase Endogenous HSCs and MSCs
  • No Increase in IL-6 and GM-CSF
  • Spares Platelets, RBCs and HSCs
  • No CRS, neuroedema, angiodema, fatal infusion reactions

Temodar, Rituximab, etc.

  • No Bone Marrow Redistribution
  • Deplete Peripheral Blood Lymph
  • Decrease Adoptive Cell Transfer (ACT) Binding in Spleen
  • Decrease Thymocytes
  • Increase in IL-2, IL-7, IL-12 and IL-15
  • Decrease Endogenous HSCs and MSCs
  • Increase in IL-6 and GM-CSF
  • Deplete Neutrophils, Platelets and RBCs
  • CRS, neuroedema, angiodema, fatal infusion reactions

Leave us your info

and we will get back to you.